產品 藥物探索 臨床前試驗 臨床一期 臨床二期 臨床三期 藥證申請 上市銷售
TMB-365/TMB-380 (TMB-365 與 TMB-380 的雙抗體複方組合)

TMB-365/TMB-380 (TMB-365 與 TMB-380 的雙抗體複方組合)

TMB-365 TMB-380 的雙抗體複方組合

 

TMB-365與TMB-380雙抗體複方組合(dual antibody combination)對當下流行的HIV-1變異株具有廣泛的抗病毒功效,並且TMB-365和TMB-380亦因各自在人體中具有長於一般免疫球蛋白之血中半衰期從而擁有長效藥物動力特性。一如其已在臨床驗證中的同儕3BNC117和 10-1074,TMB-365 與 TMB-380 的雙抗體組合可用於 HIV-1 治療和/或預防目的。[1, 2, 3]  目前,中裕新藥規劃朝向將TMB-365和TMB-380 雙抗體複方組合研發用於治療HIV-1病毒已被抗病毒藥物遏制之患者。[4, 5]

 

Reference

  1. Cohen YZ et al., “Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.” PLOS ONE (2019)
  2. Julio CC et al., “Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates” J. Virol. (2021) 95: e01909-20
  3. Wagh K et al., “Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection” PLOS Pathogens (2016)
  4. ViiV Healthcare Press and News Release: ViiV Healthcare to Present New Long-term Findings from Its Innovative 2-Drug and Long-Acting HIV Medicines Portfolio at CROI 2022. 07 FEB, 2022
  5. ViiV Healthcare Press and News Release: ViiV Healthcare Announced US FDA Approval of CABENUVA (CABOTEGARVIR, RILPIVIRINE) for Use Every Two Months, Expanding the Label of The First and Only Complete Long Acting HIV Treatment. 01 FEB. 2022